LXEO Lexeo Therapeutics Inc.
Price (delayed)
$2.945
Market cap
$97.77M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.09
Enterprise value
$69.42M
We are a clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. By taking aim at the underlying genetic
Highlights
The debt has contracted by 15% YoY and by 4.6% from the previous quarter
The EPS has dropped by 118% since the previous quarter but it has surged by 75% year-on-year
LXEO's equity is down by 16% since the previous quarter but it is up by 2.9% year-on-year
LXEO's net income is down by 48% YoY and by 14% QoQ
The quick ratio has declined by 24% year-on-year and by 9% since the previous quarter
Key stats
What are the main financial stats of LXEO
Market
Valuations
Earnings
Shares outstanding
33.2M
Market cap
$97.77M
Enterprise value
$69.42M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.83
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$105.77M
Net income
-$98.33M
EBIT
-$98.2M
EBITDA
-$96.19M
Free cash flow
-$81.63M
Per share
Balance sheet
Liquidity
EPS
-$3.09
EPS diluted
-$3.09
Free cash flow per share
-$2.57
Book value per share
$3.53
Revenue per share
$0
TBVPS
$4.62
Total assets
$146.94M
Total liabilities
$30.1M
Debt
$9.92M
Equity
$116.84M
Working capital
$103.28M
Debt to equity
0.08
Current ratio
5.52
Quick ratio
5.46
Net debt/EBITDA
0.29
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-54.2%
Return on equity
-65.1%
Return on invested capital
-380.7%
Return on capital employed
-79.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LXEO stock price
How has the Lexeo Therapeutics stock price performed over time
Intraday
-5.91%
1 week
-26.19%
1 month
2.97%
1 year
-79.83%
YTD
-55.24%
QTD
-15.13%
Financial performance
How have Lexeo Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$105.77M
Net income
-$98.33M
Gross margin
N/A
Net margin
N/A
The operating income has plunged by 54% YoY and by 13% from the previous quarter
LXEO's net income is down by 48% YoY and by 14% QoQ
Growth
What is Lexeo Therapeutics's growth rate over time
Valuation
What is Lexeo Therapeutics stock price valuation
P/E
N/A
P/B
0.83
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has dropped by 118% since the previous quarter but it has surged by 75% year-on-year
The P/B is 63% below the last 4 quarters average of 2.4
LXEO's equity is down by 16% since the previous quarter but it is up by 2.9% year-on-year
Efficiency
How efficient is Lexeo Therapeutics business performance
Lexeo Therapeutics's return on equity has surged by 100% YoY but it has decreased by 13% QoQ
Lexeo Therapeutics's ROIC has soared by 81% from the previous quarter and by 28% YoY
The ROA has contracted by 12% from the previous quarter but it has grown by 3.4% YoY
Dividends
What is LXEO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LXEO.
Financial health
How did Lexeo Therapeutics financials performed over time
The quick ratio has declined by 24% year-on-year and by 9% since the previous quarter
Lexeo Therapeutics's current ratio has decreased by 23% YoY and by 7% from the previous quarter
The debt is 92% less than the equity
The debt to equity has contracted by 20% YoY but it has grown by 14% from the previous quarter
LXEO's equity is down by 16% since the previous quarter but it is up by 2.9% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.